Krystal's KB113 Shrank 83% of Lesions. The Trial Had Three Patients.
An HSV-1 vector carrying IL-2 and IL-12 shrank 69 of 83 basal cell carcinomas in three Gorlin syndrome patients, including tumors it never touched. Krystal is talking to the FDA, and the caveats are as large as the signal.